Evidence map›Paper›PMID 29989017›Full record

ArticleKidney international reports2018

Mild Albuminuria Is a Risk Factor for Faster GFR Decline in the Nondiabetic Population.

Toralf Melsom, Marit Dahl Solbu, Jørgen Schei, Vidar Tor Nyborg Stefansson, Jon Viljar Norvik, Trond Geir Jenssen, Tom Wilsgaard, Bjørn Odvar Eriksen

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. High measured GFR as a predictor of all-cause mortality and cardiovascular disease in a prospective non-diabetic population cohort.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Toralf MelsomMetabolic and Renal Research Group, UiT The Arctic University of Norway, Oslo, Norway.
Marit Dahl SolbuMetabolic and Renal Research Group, UiT The Arctic University of Norway, Oslo, Norway.
Jørgen ScheiMetabolic and Renal Research Group, UiT The Arctic University of Norway, Oslo, Norway.
Vidar Tor Nyborg StefanssonMetabolic and Renal Research Group, UiT The Arctic University of Norway, Oslo, Norway.
Jon Viljar NorvikMetabolic and Renal Research Group, UiT The Arctic University of Norway, Oslo, Norway.
Trond Geir JenssenMetabolic and Renal Research Group, UiT The Arctic University of Norway, Oslo, Norway.
Tom WilsgaardDepartment of Community Medicine, UiT The Arctic University of Norway, Oslo, Norway.
Bjørn Odvar EriksenMetabolic and Renal Research Group, UiT The Arctic University of Norway, Oslo, Norway.
UiT The Arctic University of Norway · NOUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA minimal increase in the albumin-to-creatinine ratio (ACR) predicts cardiovascular disease and mortality, but whether it predicts kidney function loss in nondiabetic persons is unclear. We investigated the association between ACR in the optimal or high-normal range and the rate of glomerular filtration rate (GFR) decline in a cohort from the general population without diabetes, cardiovascular, or chronic kidney disease.

methodsIn the Renal Iohexol Clearance Survey, we measured GFR using iohexol clearance in 1567 middle-aged nondiabetic individuals with an ACR <3.40 mg/mmol (30.0 mg/g) at baseline. The ACR was measured in unfrozen morning urine samples collected on 3 days before the GFR measurements. A total of 1278 (81%) participants had follow-up with GFR measurements after a median of 5.6 years.

resultsThe median ACR at baseline was 0.22 mg/mmol (interquartile range: 0.10-0.51 mg/mmol), the mean ± SD GFR was 104.0 ± 20.1 ml/min, and the mean ± SD GFR decline rate was -0.95 ± 2.23 ml/min per year. Higher baseline ACR levels were associated with a steeper GFR decline in adjusted linear mixed models. Study participants with ACR levels of 0.11 to 0.45 and 0.46 ± 3.40 mg/mmol had a 0.25 ml/min per year (95% confidence interval [95% CI]: -0.03 to 0.53) and 0.31 ml/min per year (95% CI: 0.02-0.60) steeper rate of decline than those with ACR ≤0.10 mg/mmol in multivariable-adjusted analyses. Among study participants with an ACR of <1.13 mg/mmol (defined as the optimal range), those with an ACR of 0.11 to 1.12 mg/mmol (n = 812) had a 0.28 ml/min per year (95% CI: 0.04-0.52) steeper rate of GFR decline than those with an ACR of ≤0.10 mg/mmol (n = 655).

conclusionA mildly increased ACR is an independent risk factor for faster GFR decline in nondiabetic individuals.

Indexed as

ACRalbumin-creatinine-ratioGFRiohexol clearance

Identifiers

PMID29989017
PMCPMC6035129
OpenAlexW2789361693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.